Financial Data and Key Metrics Changes - The company reported cash, cash equivalents, and marketable securities totaling $41.3 million as of September 30, 2023, which is expected to support operations into the first quarter of 2025, one quarter longer than previously anticipated [34] - Total revenues for the third quarter were $1.2 million, a decrease of $1.8 million compared to approximately $3 million for the same period in 2022, primarily due to lower collaboration and licensing revenue from the Roche agreement [35] - Total operating expenses were $7.8 million, a slight decrease from $8 million in the same period in 2022, with R&D expenses increasing to $3.7 million from $3.6 million [36] - The net loss was $7.1 million or $0.04 per share, compared to a net loss of $6.1 million or $0.04 per share for the same period in 2022 [38] Business Line Data and Key Metrics Changes - The ANP1 program for hearing loss has advanced to the next phase of preclinical development, with positive initial proof of concept results [22][24] - The VAC platform is being treated as a business development project rather than an internal clinical development program due to the current biotech environment [18] Market Data and Key Metrics Changes - The global spinal cord therapy market is referenced upwards of $7 billion to $10 billion, indicating significant market potential for the company's spinal cord injury program [62] Company Strategy and Development Direction - The company is focusing on maintaining financial discipline to navigate the challenging biotech environment while continuing to advance its key programs [29] - The collaboration with Eterna Therapeutics aims to leverage proprietary process development capabilities combined with external cell engineering technologies to create novel product candidates [27][28] Management's Comments on Operating Environment and Future Outlook - Management noted that the ongoing conflict in Israel has not materially impacted operations, and the company remains committed to advancing its business [32] - The company is optimistic about the potential of its lead asset, OpRegen, and is eager to complete the final steps for the OPC1 IND amendment [32][58] Other Important Information - The company has patented new process development methods to support long-term exclusivity for its pipeline, including a patent for large-scale production of retinal pigment epithelial cells [57] Q&A Session Summary Question: Inquiry about OpRegen Phase 2a and its impact on study conduct - Management indicated that the initial clinical outcomes could ease conversations between investigative sites and patients, potentially facilitating quicker enrollment [14] Question: Timeline for preclinical data on ANP1 and interest in the VAC platform - Management stated that functional preclinical data for ANP1 is expected in 2024, and the VAC platform is being pursued through partnerships rather than internal development [16][18] Question: Status of tech transfer at Roche - Management confirmed that tech transfer is on target, but specific details could not be disclosed [71]

For the quarterly period ended September 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Lineage Cell Therapeutics, Inc. (Exact name of registrant as specified in its charter) California 94-3127919 (State or other jurisdiction of incorporation or organization) (IRS Employer Identifica ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _________ to ________ Commission file number 001-12830 Lineage Cell Therapeutics, Inc. (Exact name of registrant as specified in its charter) California 94-3127919 (State ...

Lineage Cell Therapeutics, Inc. (NYSE:LCTX) Q1 2023 Results Conference Call May 11, 2023 4:30 PM ET Company Participants Ioana Hone - Head of Investor Relations Brian Culley - Chief Executive Officer Jill Howe - Chief Financial Officer Gary Hogge - Senior Vice President of Clinical and Medical Affairs Conference Call Participants Jack Allen - Baird Joe Pantginis - H. C. Wainwright Kristen Kluska - Cantor William Wood - B. Riley Michael Okunewitch - Maxim Group Operator Welcome to the Lineage Cell Therapeuti ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _________ to ________ Commission file number 001-12830 Lineage Cell Therapeutics, Inc. (Exact name of registrant as specified in its charter) California 94-3127919 (Stat ...

Lineage Cell Therapeutics, Inc. (NYSE:LCTX) Q4 2022 Earnings Conference Call March 9, 2023 4:30 PM ET Company Participants Ioana Hone - Head of IR Brian Culley - CEO Jill Howe - Chief Financial Officer Gary Hogge - SVP, Clinical and Medical Affairs Conference Call Participants Jack Allen - Baird William Wood - B. Riley Securities Kristen Kluska - Cantor Fitzgerald Joe Pantginis - HC Wainwright Joanne Lee - Maxim Group Operator Welcome to the Lineage Cell Therapeutics Fourth Quarter and Full Year 2022 Confer ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from___________ to __________ Commission file number 001-12830 Lineage Cell Therapeutics, Inc. (Exact name of registrant as specified in its charter) (State or other jurisdiction ...

Lineage Cell Therapeutics, Inc. (NYSE:LCTX) Q3 2022 Earnings Conference Call November 10, 2022 4:30 PM ET Company Participants Ioana Hone - Head of IR Brian Culley - CEO and Interim CFO Gary Hogge - SVP, Clinical and Medical Affairs Conference Call Participants William Wood - B. Riley Securities Rick Miller - Cantor Fitzgerald Michael Okunewitch - Maxim Group Operator Welcome to the Lineage Cell Therapeutics Third Quarter 2022 Conference Call. At this time, all participants are in a listen-only mode. An aud ...

Start Time: 16:30 January 1, 0000 5:18 PM ET Lineage Cell Therapeutics, Inc. (NYSE:LCTX) Q2 2022 Earnings Conference Call August 11, 2022, 16:30 PM ET Company Participants Brian Culley - CEO and Interim CFO Gary Hogge - SVP, Clinical and Medical Affairs Ioana Hone - Head of IR Conference Call Participants William Wood - B. Riley Securities Rick Miller - Cantor Fitzgerald Joe Pantginis - H.C. Wainwright Jason McCarthy - Maxim Group Operator Welcome to the Lineage Cell Therapeutics Second Quarter 2022 Confer ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _________ to ________ Commission file number 001-12830 Lineage Cell Therapeutics, Inc. (Exact name of registrant as specified in its charter) California 94-3127919 (State ...